ALX Oncology logo

ALX Oncology

ALXO | NASDAQ
Chart Builder DCF Calculator
$1.00
-$0.04 (-3.85%)
At close: Nov 16, 2026, 4:00 PM ET
$0.98
-$0.02 (-2.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.85%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
35.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #638/1021 (Top 62%)

Key Statistics

Market Data

Market Cap $138.28M
1D Range
0.91 1.07
52W Range
0.89 2.60

Valuation (TTM)

PE -0.88
PB 1.02
EV/EBITDA -0.12

Valuation (NTM)

Forward PE N/A
Forward PEG 0.01
Price Target $4.00
Loading financial charts...

Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD...

Sector Healthcare
Industry Biotechnology
Employees 48
IPO Date Jul 17, 2020
Fiscal Year January - December

Latest News

No news articles available yet.

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$4.00
Upside
+300.00%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.